• Date: March 13, 2018

Founded at the Bellvitge Biomedical Research Institute (IDIBELL), ADmit Therapeutics is aiming to develop a diagnostic test to detect Alzheimer's disease in its very early stages.

It is the fifth spin-off that has resulted from the CaixaImpulse programme, in this case from the Kit for early Alzheimer's detection project from 2015, led by Marta Barrachina. Barrachina is the general director of the new company, and is joined by Ramón Reñé and Jordi Gascón as medical advisory board.

The in vitro diagnostic test developed by ADmit Therapeutics determines whether certain mitochondrial biomarkers are present in the blood. These biomarkers can indicate signs of the disease before the brain starts producing the protein aggregates that characterise Alzheimer's. Early diagnosis would allow those affected to start receiving the treatments available to slow down the progress of the disease, as there are still no treatments to reverse it. The company is seeking private investors as a step towards CE certification.

More programme highlights

June 21, 2018

“SMuFin detects genomic mutations of all kinds more efficiently than other software programs”

Founded at the Barcelona Supercomputing Centre, SMuFin is a software program that offers promising advances in personalised medicine. We spoke to Ezequiel Mas, the project manager during CaixaImpulse, to find out more.

May 31, 2018

The KAMLEON project receives a number of awards

Founded at the Rovira i Virgili University, KAMLEON is developing a cloud platform capable of monitoring hydration levels through urine and sweat sensors.

May 03, 2018

Three editions of CaixaImpulse at a glance

When the call for proposals for the fourth edition of CaixaImpulse just closed, it is a good chance to take stock of what previous editions of the programme have meant.